BULK DRUGS & INTERMEDIATES MANUFACTURING...

PRE FEASIBILITY REPORT

OF

M/S. TEJASHRRI INTERMEDIATES PRIVATE LIMITED.

#FLAT No – 303, Varnica Arcade, B-88, Madhuranagar, Hyderabad - 500038

BULK DRUGS & INTERMEDIATES

MANUFACTURING UNIT

At

PLOT NO.133 to 142, PHASE – II, IDA

PASHAMAILARAM (V), PATANCHERU (M),

MEDAK DISTRICT, ANDHRA PRADESH.

Contents

S. No. Description Page no. 1.0 Executive Summary 1 2.0 Introduction of The Proposed Project 2 2.1 Project Proponent 2 2.2 Brief description of nature of the project. 3

2.3 Need for the project and its importance to the country and or region 3

2.4 Demand-Supply Gap. 5

2.5 Employment Generation(Direct and Indirect) due to the project 5

3.0 Project description 6 3.1 Products and Production Capacity 7 3.2 Raw materials required and Quantities 8-12 3.3 Manufacturing Process 13 3.4 Resource – Utilize and Recycling 13

3.4.1 Water 13

3.4.2 Power Requirement 14

3.4.3 Fuel Requirement 14 3.5 Quantity of wastes to be generated 14

3.5.1 Waste Water Generation and utilization 14 3.5.2 Solid waste generation and Disposal 15

3.6 Schematic representations of the feasibility drawing which give information of EIA purpose. 15

4.0 Site Analysis 16 4.1 Connectivity 16 4.2 Land Form, Land use and Land ownership. 16 4.3 Existing Infrastructure 16 4.4 Soil classification 16 4.5 Climatic data from secondary sources. 17 4.6 Social Infrastructure available. 17 5.0 Planning brief 17 6.0 Proposed infrastructure 17 6.1 Industrial Area 17 6.2 Residential Area 17 6.3 Green Belt: 17 6.4 Social Infrastructure 18

6.5 Water management 18 6.6 Sewerage System 18 6.7 Industrial Waste Management 18 7.0 Rehabilitation and Resettlement (R&R) Plan 18 8.0 Project Schedule and Cost estimates 18 9.0 Analysis of project 19

LIST OF TABLES

Table No Description Page no. 3.1 Existing Products and Quantities 8 3.2 Proposed Products and Quantities 8 3.3 Bromophenaramine 9 3.4 Butaphosphan 9 3.5 Carsiprodol 9 3.6 Ciprofloxacin hydrochloride 10 3.7 Diltiazem Hydrochloride 10 3.8 Famotidine 11 3.9 Metformin Hydrochloride 11

3.10 Risperidone 11 3.11 Terbinafine Hydrochloride 12 3.12 Topiramate 12 3.13 Water Requirement Details 14 3.14 Wastewater generation and Treatment Method 15 8.1 Solid waste generation and Disposal 15

Project Cost 19

LIST OF FIGURES

Figure No Description Page no. 1.1 Location Map 8

LIST OF FLOW CHART

Flow Chart No Description Page no. 3.1 Generalized Flow Chart for Bulk Drug

Manufacturing 12

Pre- Feasibility Report

M/S. Tejashrri Intermediates Private Limited. 1

1.0 EXECUTIVE SUMMARY

M/s. Tejashrri Intermediates Pvt Ltd., is incorporated by experienced professionals

in the field of Bulk Drugs with the objective of producing bulk drugs and bulk drug

intermediates with registered address at Flat No.303, Varnica Arcade, B-88,

Madhuranagar, Hyderabad-500038.

The company has it’s bulk drug and intermediate manufacturing facility at Plot

No.133 to 142, Phase – II, IDA Pashamailaram (V), Patancheru (M), Medak (DT),

Andhra Pradesh.

S. No Parameter Description

1 Project Location

Plot No.133 to 142, Phase – II, IDA Pashamailaram

(V), Patancheru (M), Medak (Dt), Andhra Pradesh

2

Category of Project as per EIA Notification & Amendments 5(f) “A”

3 Project cost 18.8173 Crores 4 Plot area 2.52 Acres

5 Proposed Product 3600TPA 6 Resources

(i)Electricity Requirement

Source of electricity APCPDCL- 800KVA

D. G. Sets 125 KVA, 380 KVA & 250KVA are available to meet emergency power requirement of the plant.

(ii)Water consumption 135.69 KLD

Source of water APIIC Water Supply Waste water generation 58.32 KLD Mode of disposal Zero Liquid Discharge System

(iii)Boiler 3.0 & 2.0 TPH Boiler

(iV)Fuel Coal - 12.5 MT / Day

7 Solid waste generation Mentioned in Para 3.1 of report 8 Nearest Highway National Highway No.9 -1.5 KMs 9 Nearest Railway Station Lingampally Railway Station – 16 KMs 10 Nearest Air Port Rajeev Gandhi International Air port- 43 KMs



2.0 INTRODUCTION OF THE PROJECT

The objective of this pre‐feasibility study is to provide information for the proposed

expansion of Bulk Drugs and Intermediates manufacturing unit by M/s. Tejasri Intermediates Private Limited (TIPL) at Plot No.133 & 142, Phase – II, IDA

Pashamailaram (V), Patancheru (M), Medak (DT), Andhra Pradesh.

TIPL is one of the fastest growing Active Pharmaceutical Ingredients, Specialty Fine

Chemicals & Bulk Drug Intermediates manufacturing company established in 1996 in

Hyderabad, India. Which have specialty in synthesis molecules and chemistry

preparation. We are bulk drug intermediates manufacturer, supplier & exporter. We

have very strong team of Technocrats and Technical people engaged mainly into the

new molecule development. We have been engaged continuously into custom

synthesis & contract manufacturing of new molecules for various MNC companies.

We have fully integrated manufacturing facilities in Hyderabad, India, which includes

Glass Lined Reactor, S.S. Reactor, Fractional Distillation, High Vacuum System,

Driers, Centrifuges, Thermic Fluid and Steam Generation Boiler. Our facility is

equipped with the instruments like HPLC, GC and IR & UV.

We are handling specialized reactions like Fries Rearrangement, Witting reaction,

Grignard reaction etc…, similarly handling Bromination, Chlorination, Cyanation,

Diazotization, Hydrolysis, Hydrogenation, Nitration, Reduction etc. At plant level.

The company is now aim towards the international market & as our first step to it; we

have started implementation of ISO, which is expected to be completed by 2010.

2.1 Project Proponent M/s. Tejasri Intermediates Private Limited is incorporated by Sri. Jagaavarapu. Sanjeeva Reddy is the Managing Director of this Company having more than two

decades of rich industrial experience in this line of activity. He supervises the overall

affairs of the company.



Sri. J. Parvathi Devi is the Director of TIPL and has work experience more than

20years in different bulk drug industries.

2.2 Brief description of nature of the project. The proposed expansion is to manufacture Bulk Drugs and intermediate, which are

active ingredients with medicinal properties.

2.3 Need for the project and its importance to the country and or region The company is engaged in the manufacturing of bulk drugs & intermediates and is

planning to increase its capacity along with distillation of solvents.

The project in general holds significance for an emerging country like India where

health care costs are increasing by the day due to demand supply gap in affordable

medicines. Moreover due to low cost and hi technology the bulk drugs manufactured

in India has immense export potential with consequent possibility of foreign

exchange earnings

Hyderabad has emerged as major drug manufacture city with a presence in global

market. Pharma industry in the state contribute more than one third to the country’s

total production.

Most of the companies have set up their R&D facilities in the state, thus making the

state the pharmaceutical capital of the country.

Hyderabad has developed as a major production center for bulk drugs due to the

location if the many major Pharmaceutical Industries such as Dr. Reddy’s

Laboratories, Aurobindo Pharma, Neuland Laboratories, Siris, Hetaro Drugs, Divis

Labs, Natco Pharma Limited, Matrix Labs, Nicholas Piramal etc., besides a large

number of medium and small industries manufacturing bulk drugs of all kinds.

In support of this growth in Hyderabad and Bangalore, many basic chemical units

and drug intermediate units have also come up to meet the input requirements of

Bulk Drug manufacturing Companies. Large numbers of these units are still

dependent on supply of basic chemicals mainly from Mumbai, Gujarat and other

parts of the country involving heavy expenditure on transport and transit risks.



2.3 Demand-Supply Gap. The demand for APIs and API intermediates is a derived demand. It gets derived

from the demand for various medicinal formulations (final administrable drugs) for

the formulation industry.

• The APIs and API intermediates being manufactured by basic drug

manufacturers are exported as such or used by domestic formulators in their

production processes. The formulation firms further produce final medicines

and export these as well as sell these in the domestic market.

• There is a wide gap in the demand and availability of cheap and quality

medicines in India and the world over.

• Generic medicines and off patent drugs have significant potential to increase

access to cheap and effective medicines to poor people and in general to

bridge the demand supply gap.

• Indian basic drug manufacturers are playing a significant role in increasing

access to affordable off patent drugs.

• The products envisaged include third generation antibiotics, anticancer,

antipsychotic, etc drugs which address the problems associated with present

day stressful lifestyles and demand for these outstrips their demand and is

increasing by the day.

Pharmaceutical Industry – Domestic Scenario The Indian Pharmaceutical Industry today is in the front rank of India’s Science-

based industries with wide ranging capabilities in the complex field of drug

manufacture and technology. The Indian Pharmaceutical industry is estimated to be

worth US $ 8.0 billions at present, growing at a CAGR of over 15 % annually. If

India‘ s high Economic growth rate holds steady, the pharmaceuticals market will

triple to $ 24 billion by 2015 and become one of the world` s top 10 markets

according to a study by McKinsey and company ,a leading management

consulting firm. At a compounded annual growth rate of 15.0 %, the absolute

growth of $ 24 billion will be next to the growth potential of the US and China, and in

the same league as the growth in Japan and Canada and the UK. Five factors will

drive the growth of the Indian Pharmaceuticals market over the next decade;

Doubling of disposable incomes and the increase in numbers of middle class

households , significant expansion of medical infrastructure, greater penetration of



health insurance, a gradual shift in disease profile and adoption of patented

products, and finally population growth.

It ranks very high in the third world, in terms of technology, quality and range of

medicines manufactured. Playing a key role in promoting and sustaining

development in the vital field of medicines, the Indian Pharmaceutical Industry

boasts of quality producers and many units approved by regulatory authorities in

USA and UK.

The Indian Pharmaceutical sector has more than 20,000 registered units. It has

expanded drastically in the last two decades. The leading 250 pharmaceutical

Companies control 70% of the market. The pharmaceutical industry in India meets

around 70% of the country’s demand for bulk drugs, drugs intermediates,

pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables.

There are about 250 large units and about 8000 small Scale Units, which form the

core of the pharmaceutical industry in India (including 5 Central Public Sector Units).

These units produce the complete range of pharmaceutical formulations, i.e.

medicines ready for consumption by patients and about 350 bulk drugs, i.e.

chemicals having therapeutic value and used for production of pharmaceutical

formulations.

2.4 Employment Generation (Direct and Indirect) due to the project

The project will employ permanent as well as contractual and sub-contractual

employees from surrounding areas. Estimated employment generation over a three

year period is 400 employees. Apart from this there will be significant non estimated

employment generation at the supplier firms and service industry providing services

to the company. Company shall be giving preference to people from economically

weaker sections for employment in various semi-skilled/unskilled jobs thereby

contributing to their upliftment.

.

It is expected to direct or indirect employ about 55 people of various skills will be

required during construction as well as operation phase. The Details of employment

shown in below Table.



Particulars No. of employees

Functional Area

Key managerial staff 5 Finance, Marketing, Production,

Quality control, R&D, Logistics etc.

Administration 10 Office work

Skilled and semi

skilled

40 Production Process, Maintenance,

stores, Safety.& Un skilled workers

Total 55

3.0 Project Description

M/s. Tejashrri Intermediates Private Limited., proposes expansion manufacturing

of products at Plot No.133 to 142, Phase – II, IDA Pashamailaram (V), Patancheru

(M), Medak (DT), Andhra Pradesh. The Location map is shown at Figure – 1.

The site coordinates are Latitude: 17°32'32.63"N

Longitude: 78°11'05.62"E

There are no major cities within 10 KMs radius and also no archaeological, historical

sites located nearby. Therefore, the project site does not offer any negative impact

on the local area as because it is an expansion of existing unit in notified industrial

area, but rather has a positive impact on socio economic conditions of the habitants

around it.

The proposed plant is well connected both to National Highway No– 9 and Railway

line at Lingampally Railway Station. A total of about 10096.50 SQMs of land is

required for the project.



Figure 1.1: Location Map

Plot No.133 to 142, Phase – II, IDA Pashamailaram (V), Patancheru (M), Medak (DT), AP.



3.1 Products and Production Capacity

M/s. Tejashrri Intermediates Pvt Ltd. is already producing (Table 3.1) and now the

company proposes to produce the below mentioned shown in Table3.2.

Table3.1: Existing Product and Quantity

S.NO Product Name Quantity In TPM

1 N-Butyl Lithium 200 TPM

2 Ethyl-2oxo-4-phenyl butyrate 150 TPM

Table3.2: Proposed Products and Quantities

S. No Product Name CAS No’s Quantity In Kg/Month

Quantity In Kg/Day

1 Bromophenaramine 86-22-6 5000.00 166.67

2 Butaphosphan 17316-67-5 82000.00 2733.33

3 Carsiprodol 3053-63-2 15000.00 500.00

4 Ciprofloxacin hydrochloride 86483-48-9 11000.00 366.67

5 Diltiazem Hydrochloride 33286-22-5 85000.00 2833.33

6 Famotidine 76824-35-6 15000.00 500.00

7 Metformin Hydrochloride 1115-70-4 70000.00 2333.33

8 Risperidone 106266-06-2 2000.00 66.67

9 Terbinafine Hydrochloride 78628-80-5 5000.00 166.67

10 Topiramate 97240-79-4 10000.00 333.33

Total 300000.00 10000.00

3.2 Raw materials required and Quantities All the raw materials required for manufacturing of above products will be sourced

from local market. The products wise required raw materials and quantities are

shown in below Tables 3.3-3.11.



3.3. BROMPHENIRAMINE

S. No Raw Material Consumption/ Batch in Kgs

Consumption/ Day in Kgs

1 Phenyl acetonitrile 60.00 100.00 2 Toluene 668.00 1113.33 3 Bromine 82.00 136.67 4 Sodium hydroxide 35.00 58.33 5 2-Chloro pyridine 60.00 100.00 6 Soda amide 42.00 70.00 7 2-(Dimethyl amine)ethyl chloride 50.00 83.33 8 Soda amide 38.00 63.33 9 Sodium methoxide 30.00 50.00

10 Methanol 250.00 416.67

3.4. BUTAPHOSPHAN



1 n-Butyl amine 1125.00 2562.38 2 Potassium carbonate 925.00 2106.84 3 Acetone 8200.00 18676.87 4 Hypo phosphorus acid 1470.00 3348.17 5 Acetic acid 22.50 51.25

3.5. CARISOPRODOL



1 2-Methyl-2-propyl-1,3-propane diol

78.00 390.00

2 Dimethyl carbonate 110.00 550.00 3 Toluene 810.00 4050.00 4 Sodium methoxide 6.00 30.00 5 Isopropylamine 164.00 820.00 6 Sodium cyanate 31.50 157.50 7 Chloroform 630.00 3150.00 8 Hydrochloric acid (35%) 100.00 500.00 9 Sulphuric acid 50.00 250.00

10 Methanol 335.00 1675.00 11 Activated carbon 15.00 75.00



3.6. CIPROFLOXACIN HYDROCHLORIDE



1 7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-quinoline-3-carboxylic acid

95.00 348.33

2 Piperazine 58.00 212.67 3 N-Butanol 400.00 1466.67 4 Ammonium Hydroxide 12.00 44.00 5 Acetic acid 20.00 73.33 6 Activated carbon 20.00 73.33 7 Hydrochloric acid 20.00 73.33

3.7. DILTIAZEM HYDROCHLORIDE



1 P-anisaldehdye 45.00 1275.00 2 Chloro-acetic acid methyl ester 36.00 1020.00 3 Sodium methoxide 12.00 340.00 4 Methanol 400.00 11333.33 5 2-Amino-benzenethiol 40.00 1133.33 6 Toluene 350.00 9916.67 7 Sodium hydroxide 12.00 340.00 8 L-Lysine 15.00 425.00 9 Toluene 400.00 11333.33

10 (2-Chloroethyl)-dimethyl amine Hydrochloride

40.00 1133.33

11 Ethyl acetate 500.00 14166.67 12 Potassium carbonate 25.00 708.33 13 Isopropyl alcohol HCl 117.00 3315.00 14 Acetic anhydride 25.00 708.33



3.8. FAMOTIDINE



1 1,3-Dichloro acetone 53.00 265.00 2 Guanyl thiourea 50.00 250.00 3 Potassium Iodide 2.40 12.00 4 Acetone 170.00 850.00 5 Thiourea 25.13 125.65 6 Sodium hydroxide 40.00 200.00 7 N-Sulfamyl-3-chloro

propionamidine HCl 74.00 370.00

8 Acetic acid 25.00 125.00 9 Methanol 3436.00 17180.00

10 Ammonia (23%) 24.00 120.00 11 Activated carbon 6.00 30.00

3.9. METFORMIN HYDROCHLORIDE



1 Dimethylamine Hcl 630.00 1176.00 2 N-Cyano guanidine 650.00 1213.33 3 Xylene 1550.00 2893.33 4 Activated carbon 2.00 3.73 5 Hyflo 2.00 3.73 6 Methanol 440.00 821.33

3.10. RISPERIDONE



1 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Hydrochloride

21.00 56.00

2 3-(2-Chloroethyl)-2-=Methyl-6,7,8,9-Tetrahydro-4H-pyrido [1,2-α]Pyrimidin-4-one HCl

22.00 58.67

3 Sodium bicarbonate 35.00 93.33 4 Potassium iodide 0.80 2.13 5 Methyl Isobutyl ketone 235.00 626.67 6 Sodium hydroxide 3.00 8.00 7 Isopropyl alcohol 265.00 706.67 8 DMF 6.00 16.00 9 Activated carbon 5.00 13.33

10 Hyflow 5.00 13.33



3.11. TERBINAFINE HYDROCHLORIDE



1 Napthyl methyl chloride 65.00 108.33 2 Mono methyl amine 12.00 20.00 3 Toluene 600.00 1000.00 4 Hydrochloric acid 28.00 46.67 5 Sodium hydroxide 30.00 50.00 6 MDC 500.00 833.33 7 Chloro methyl heptane 55.00 91.67 8 Potassium carbonate 25.00 41.67 9 IPA 600.00 1000.00

3.12. TOPIRAMATE



1 2,3,4,5-Bis-O-(1-Methyl Ethylidene)-β-D-fructo pyranose

48.00 320.00

2 Sulfuryl Chloride 25.00 166.67 3 Tri-n-Butyl amine 34.20 228.00 4 Ammonium Carbonate 17.72 118.13 5 Sodium Hydroxide 7.40 49.33 6 Sodium bicarbonate 8.00 53.33 7 Hydrochloric acid 6.75 45.00 8 Cyclo hexane 630.00 4200.00 9 Ethyl Acetate 740.00 4933.33 10 MDC 315.00 2100.00 11 Activated Carbon 10.00 66.67



3. 3 Manufacturing Process The manufacturing process of bulk drugs consists of chemical synthesis extending

to stages of processing involving different type of chemical reactions. The

generalized Flow chart for bulk drug manufacturing is shown in Flow chart 3.1.

Flow Chart 3.1: Generalized Flow Chart for Bulk Drug Manufacturing

3.4 Resource – Utilize & Recycling 3.4.1 Water Water requirement of the project for domestic and industrial activity during operation

phase will be 135.69 KLD. The water requirement will be met through IDA. The

detailed water requirement shown in below Table3.12.



Table 3.12: WATER REQUIREMENT DETAILS

S. No Purpose Water Requirement In KLD

1 Process 32.69 2 Washings 2.00 3 Boiler Make up 29.00 4 Cooling towers Make up 61.00 5 DM Plant 2.00 6 Scrubbing system 2.00 7 Domestic 2.00 8 Gardening 5.00 Total 135.69

3.3.2 Power Requirement Power requirement of proposed project will be made available through APCPDCL.

Total power requirement of proposed plant shall be 800KVA.

Two No’s of D. G. sets of capacity 125 KVA, 380 KVA & 250KVA are available to

meet emergency power requirement of the plant.

3.4.3 Fuel Requirement It is proposed to install 3.0 TPH & 2.0 TPH coal fired boiler. Total fuel requirement

will be around 12.5 TPD. Coal is procured form local sources. 3.5 Quantity of wastes to be generated

3.5.1 Waste Water Generation and utilization

Total effluent generated in the project is 58.32 KLD. The treated water will be reused

for plant operations.

The process waste water from Process, floor Washes, scrubbers, QC and R&D are

evaporated in MEE with stripper and ATFD after neutralization. The condensate from

MEE and ATFD will be collected and treated in effluents treatment plant along with

effluents from utilities followed by RO. RO rejects will be send back to MEE and RO

Permeate will be re-used back.



To treat the sewage generated due to domestic activities will be disposed through

septic tank following by soak pit.

Table3.13: Wastewater generation and Treatment Method

S.NO Effluent Generation Unit Effluent Generation

In KLD 1 Process 35.32 2 Washings 2.00 3 Boiler Blow Down 4.00 4 Cooling towers Blow Down 11.00 5 Scrubber System 2.00 6 DM Plant 2.00 7 Domestic 2.00

Total 58.32

3.5.2Solid waste generation and Disposal The types of Hazardous and non Hazardous wastes generated from the project,

method of disposal is shown in below table3.14. Table 3.14: Solid waste generation and Disposal

S. No Name of the Solid Waste Quantity Kg/Day

Disposal Method

1 Inorganic Solid Waste 824.00 Sent to TSDF 2 Organic solid waste 5428.00 Sent to Cement Industries 3 MEE Salts 2043.00 Sent to TSDF 4 Spent Carbon 278.00 Sent to Cement Industries 5 ETP Sludge 100.00 Sent to TSDF 6 Distillation bottom Residue 150.00 Sent to TSDF 7 Coal ash from boiler 5875.00 Sent to Brick Manufacturers

3.6 Schematic representations of the feasibility drawing which give

information of EIA purpose. The applicability of the S.O 1533 for the proposed project was explored by

considering different possibilities & provision made in the said notification.

Considering the products & project location of the proposed project it is noticed that

the proposed project falls under Category 5 (f) “A” of the Schedule-I of EIA

Notification SO 1533.



As per the provision of the SO 1533, it is necessary to get Environmental Clearance

by applying to MoEF along with the Environmental Impacts Assessment Study

Report for the proposed project prior to commissioning of the project activities.

Therefore the EIA is required to conduct to comply with provisions of SO 1533 made

for Category 5(f) “A” of schedule –I of the notification.

4.0Site Analysis

4.1 Connectivity M/s Tejashrri Intermediates Private Limited. is located at Plot No.133 & 142, Phase

– II, IDA Pashamailaram (V), Patancheru (M), Medak (DT), Andhra Pradesh..

• The nearest habitation from the site is Pashamailaram (Village) at a distance

of 1.5Km.

• The nearest railway station is Lingampally Railway station at a distance of 16

KMs from the site.

• The nearest airport is Rajeev Gandhi International Air port at a distance of 43

KMs at Samshabad, Hyderabad.

• The Nearest road ways

National Highway No.9 – 1.5KMs Outer Ring Road of Hyderabad – 5.4 KMs

4.2 Land Form, Land use and Land ownership. The proposed expansion is in existing land only and the project location is in Notified

Industrial Area.

There would be no any change in Land Use, Land Cover or Topography of plot. After

implementation of project a dense green belt would be developed.

The total

4.3 Existing Infrastructure. Proposed project is a existing facility and the basic infrastructure is already there. 4.4 Soil classification The district is mainly covered by three types of soils Sandy Loan, Black clay Loam,

Laterate types of soil.



4.5 Climatic data from secondary sources. Temperature Maximum: 46.3o C Minimum: 10.8 o C

Normal annual rainfall 873 mm 4.6 Social Infrastructure available. Well developed social infrastructure facilities are available at nearby Habitations.

5.0 Planning Brief

Proposed plant expansion activities will be started after getting statutory clearance

form related authorities. The project will be completed within two years.

Further proposed project activities will take care of all the rules and regulation of

statutory authority and provide the control measure and devices to achieve the

standard norms

6.0 Proposed Infrastructure 6.1 Industrial Area

Basic infrastructure developed already and the required plant and machineries will

be installed after getting statutory clearance.

6.2 Residential Area

No residential area is involved in the proposed project. The employs are accommodated in nearby Residential areas 6.3 Green Belt: Approximately 3396.00SQM of Green Belt will be provided and maintained. 6.4 Social Infrastructure: Facilities like road and communication are good.Banks; ATM's and medical facilities are also adequate.



Amenities: Education- schools including middle, secondary and higher secondary schools, social welfare hostels. Medical and Health- Community Health Centre, & Primary Health center Are available near villages Power and water- All the villages are electrified and drinking water facilities are extended to all villages. Rail and Road- The project site is very well connected by road through National Highway no. 9, Southern railways. 6.5 Water management Water requirement will be fulfilled through Industrial Development Authority. 6.6 Sewerage System: There will be no discharge of industrial effluent (Zero Liquid Discharge). The treated effluent will be reused. Domestic waste water will be disposed off through soak pit system.

6.7 Industrial Waste Management: Due to proposed project, the effluent from cooling and Plant/Equipment washing will

be generated and treated in the well designed Effluent Treatment Plant. The treated

effluent will be reused.

7.0 Rehabilitation and Resettlement (R & R) Plan

Rehabilitation & Resettlement (R&R) plan is not applicable to proposed project.

8.0 Project Schedule & Cost Estimates

Proposed project activities will be started after getting statutory clearance form

related authorities. The project will be completed within two years.



Table 8.1: Project Cost

S. No Particulars Amount Rs in lakhs Existing Expansion Total

1. Land & Site development 41.73 0.00 41.73 2. Building &Civil works 337.05 262.95 600.00 3. Plant and Machinery 169.32 815.68 985.00 4. Furniture, Fixtures and other assets 11.62 8.38 20.00 5. Vehicles 24.69 25.31 50.00 6. Preliminary Pre operative 0.00 40.00 40.00 7. Liasoning work 0.00 20.00 20.00 8. Marginal money for working capital 16.25 108.75 125.00

Total 600.66 1281.07 1881.73 Means of Finance 1 Promoters Capital 470.00 160.00 630.00 2 Term Loan 130.66 1121.07 1251.73

Total 600.66 1281.07 1881.73

9.0 Analysis of proposal (Final Recommendations)

Proposed expansion activity will provide benefits to the local people in terms of

financial and social welfare.

Local people will get direct financial benefit by way of employment.

Local people will get some contracts of supply and services to get indirect

income.

Company will contribute in improving education and health facilities in nearby

area.

Date post:	06-Feb-2018
Category:	Documents
Upload:	vandat
View:	236 times
Download:	4 times

BULK DRUGS & INTERMEDIATES MANUFACTURING...

Documents